Mangoceuticals (NASDAQ:MGRX – Get Free Report) is one of 18 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its rivals? We will compare Mangoceuticals to related businesses based on the strength of its valuation, institutional ownership, risk, analyst recommendations, profitability, dividends and earnings.
Insider & Institutional Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Mangoceuticals and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
Mangoceuticals Competitors | -816.62% | -48.14% | -36.60% |
Valuation and Earnings
Gross Revenue | Net Income | Price/Earnings Ratio | |
Mangoceuticals | $866,792.00 | -$9.21 million | -5.84 |
Mangoceuticals Competitors | $2.39 billion | $82.32 million | 13.32 |
Mangoceuticals’ rivals have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Mangoceuticals and its rivals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
Mangoceuticals Competitors | 36 | 288 | 416 | 147 | 2.76 |
As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 14.80%. Given Mangoceuticals’ rivals higher possible upside, analysts plainly believe Mangoceuticals has less favorable growth aspects than its rivals.
Volatility & Risk
Mangoceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ rivals have a beta of 4.14, meaning that their average share price is 314% more volatile than the S&P 500.
Summary
Mangoceuticals rivals beat Mangoceuticals on 9 of the 10 factors compared.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.